Recombinant Anti-CD19 x Anti-CD28 Bispecific Antibody (Fv-IgG) (BSDG-040)

Recombinant Anti-CD19 x Anti-CD28 Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CD19 IgG with similar domains from an anti-CD28 antibody via short peptide linkers, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD28

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Follicular lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD19 x Anti-CD28 Bispecific Antibody (Fv-IgG) (BSDG-040). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD19 x Anti-CD28 Bispecific Antibody (Fv-IgG) (CAT#: BSDG-040)

Specifications

Targets

Customer Reviews and Q&As